Ultomiris®
What is Ultomiris®?
Ultomiris® (ravulizumab-cwvz) is a long-acting C5 complement inhibitor used to treat certain rare, complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
Ultomiris® is classified as a humanized monoclonal antibody — a specially engineered type of antibody designed to be less likely to trigger an immune response when given to humans.
How does Ultomiris® work?
Ultomiris® works by targeting and blocking the C5 protein, a key part of the complement system — an important component of the body’s immune defenses.
In diseases like PNH and aHUS, the complement system becomes overactive, leading to the destruction of red blood cells (hemolysis) and damage to blood vessels.
By inhibiting the C5 protein, Ultomiris® helps prevent this harmful overactivation, protecting red blood cells and blood vessels, and helping to control the symptoms and complications of these conditions.
How much does Ultomiris® cost?
Ultomiris® cost can vary depending on several factors including insurance status and insurance provider. Our team at Rocky Mountain MS Clinic are committed to lowering costs and improving access for our patients.
We work with virtually all leading commercial insurance providers in the greater Intermountain region, including Aetna, Anthem, Blue Cross Blue Shield, Cigna, DMBA, EMI Health, Humana, PEHP Health & Benefits, Select Health, as Tricare, as well as Medicaid and Medicare.
We’re here to make treatment more affordable and less stressful. Our team takes care of prior authorizations and benefits verification for you, and we’ll personally guide you through copay assistance and foundation support programs to help lower your out-of-pocket costs.
Why Patients Choose Rocky Mountain Infusion Center to Receive Their Ultomiris® Infusion:
Clinical Excellence and Neurological Expertise
Our infusion center is proud to have a board-certified neurologist on-site, along with a team of BSN-prepared and Multiple Sclerosis-certified Registered Nurses, all committed to delivering the highest standard of care for our patients.
Lower Costs and Financial Assistance
We handle prior-authorization, benefits verification, and guide patients through copay assistance and foundation programs to reduce out-of-pocket costs. Additional financial help may be available if you qualify — just ask, and we’ll help you explore every option.
A Cigna report recently found that with a physician-owned infusion site, like RMMSC’s Infusion Center, patients see much lower out-of-pocket and overall costs than they would at a hospital outpatient infusion center.
Established leader in MS & Neurological care
35+ years in the Intermountain region, serving thousands of individuals with MS and other neurological disorders.
The infusion clinic nurses are highly trained in Neurological conditions, personable, professional and careful. Having a doctor and team like this on your side of the fight against MS is invaluable.
They are constantly improving their in-house infusion center to ensure the comfort of their patients. The team there is professional and highly trained!
As someone who frequents their infusion center on a monthly basis, I can confidently say that it's top-notch. The staff at the infusion center are amazing, providing not only excellent medical care but also creating a comfortable and soothing environment for patients. Their dedication to patient comfort and well-being is evident in every aspect of the center.
Important Info
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Atypical Hemolytic Uremic Syndrome (AHUS)
Generalised Myasthenia Gravis
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Paroxysmal Nocturnal Hemoglobinuria (PNH): Approved on December 21, 2018
Atypical Hemolytic Uremic Syndrome (AHUS): Approved on October 18, 2019
Generalised Myasthenia Gravis: Approved on April 28, 2022
Neuromyelitis Optica Spectrum Disorder (NMOSD): Approved on March 25, 2024
Alexion Pharmaceuticals, Inc.